Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Large Molecule Therapeutics

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity

Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan
Zeliang Zheng
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ryuhei Okada
2Laboratory of Molecular Theranostics, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ryuhei Okada
Hisataka Kobayashi
2Laboratory of Molecular Theranostics, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadanobu Nagaya
2Laboratory of Molecular Theranostics, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Junxia Wei
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qi Zhou
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fred Lee
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tapan K. Bera
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yun Gao
3Selecta Biosciences, Watertown, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William Kuhlman
3Selecta Biosciences, Watertown, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chin-Hsien Tai
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ira Pastan
1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ira Pastan
  • For correspondence: pastani@mail.nih.gov
DOI: 10.1158/1535-7163.MCT-19-0890 Published March 2020
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: December 2019 to February 2021

AbstractFull-text HTMLPDF
Total1531167352

Cited By

Article Information

Volume 19, Issue 3, pp. 812-821

DOI 
https://doi.org/10.1158/1535-7163.MCT-19-0890
PubMed 
31871266

Published By 
American Association for Cancer Research
Print ISSN 
1535-7163
Online ISSN 
1538-8514
History 
  • Received September 13, 2019
  • Revision received October 11, 2019
  • Accepted December 13, 2019
  • Published first December 23, 2019.

Article Versions

  • Previous version (December 23, 2019 - 07:23).
  • Previous version (February 20, 2020 - 07:23).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2019 American Association for Cancer Research.

Author Information

  1. Zeliang Zheng1,
  2. Ryuhei Okada2,
  3. Hisataka Kobayashi2,
  4. Tadanobu Nagaya2,
  5. Junxia Wei1,
  6. Qi Zhou1,
  7. Fred Lee1,
  8. Tapan K. Bera1,
  9. Yun Gao3,
  10. William Kuhlman3,
  11. Chin-Hsien Tai1, and
  12. Ira Pastan1,*
  1. 1Laboratory of Molecular Biology, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  2. 2Laboratory of Molecular Theranostics, Center for Cancer Research, NCI, NIH, Bethesda, Maryland.
  3. 3Selecta Biosciences, Watertown, Massachusetts.
  1. ↵*Corresponding Author:
    Ira Pastan, Laboratory of Molecular Biology, National Cancer Institute, 37 Convent Drive, Room 5106, Bethesda, MD 20892-4264. Phone: 240-760-6470; Fax: 240-541-4501; E-mail: pastani{at}mail.nih.gov
View Full Text
PreviousNext
Back to top
Molecular Cancer Therapeutics: 19 (3)
March 2020
Volume 19, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan
Mol Cancer Ther March 1 2020 (19) (3) 812-821; DOI: 10.1158/1535-7163.MCT-19-0890

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity
Zeliang Zheng, Ryuhei Okada, Hisataka Kobayashi, Tadanobu Nagaya, Junxia Wei, Qi Zhou, Fred Lee, Tapan K. Bera, Yun Gao, William Kuhlman, Chin-Hsien Tai and Ira Pastan
Mol Cancer Ther March 1 2020 (19) (3) 812-821; DOI: 10.1158/1535-7163.MCT-19-0890
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Conclusion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Improved Activity of CF10 in Preclinical Colorectal Cancer Models
  • Activity of ABBV-085 in Osteosarcoma
  • An Anti–CD22-seco-CBI-Dimer ADC for the Treatment of NHL
Show more Large Molecule Therapeutics
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement